Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.43 |
| ▸ | CES1 | P23141 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | CD69 | Q07108 | 2/20 | 0.41 |
| ▸ | CTSH | P09668 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6743196 | 0.85 | KMT2A (0.60) | KMT2ACD69 | |
| SCHEMBL22307832 | 0.84 | HPGD (0.37) | CES2CES1KMT2ACD69CTSH | |
| SCHEMBL19983110 | 0.83 | KMT2A (0.40) | CES2CES1KMT2ACD69CTSH | |
| SCHEMBL9722723 | 0.83 | KMT2A (0.44) | CES2CES1KMT2ACD69CTSH | |
| SCHEMBL19983011 | 0.81 | CTSK (0.47) | KMT2ACTSHCTSKMEN1 | |
| SCHEMBL4832334 | 0.80 | SMN1; SMN2 (0.43) | KMT2AMEN1 | |
| SCHEMBL22307831 | 0.79 | CTSH (0.45) | CTSHCTSK | |
| SCHEMBL6744989 | 0.77 | NLRP3 (0.59) | KMT2ANPC1MEN1RAB9AATM | |
| SCHEMBL7172967 | 0.74 | KMT2A (0.74) | KMT2ACD69NPC1RAB9A | |
| SCHEMBL3216951 | 0.74 | MAPT (0.50) | CES2CES1KMT2ACTSHCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4469073-A1 | COMPOUND FOR USE IN PREVENTING AND/OR TREATING AN INFECTION CAUSED BY SARS-COV-2 | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023139182-A1 | COMPOUND FOR USE IN PREVENTING AND/OR TREATING AN INFECTION CAUSED BY SARS-COV-2 | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2023-07-27 | — | — | WO | disclosed |
| US-11523995-B2 | Compositions and methods for ablating niche cells in testis and other epithelial cells and methods relating thereto | DUKE UNIVERSITY (US) | 2022-12-13 | — | — | US | disclosed |
| WO-2017053864-A1 | CYSTEINE PROTEASE INHIBITORS | INTRACELLULAR TECHNOLOGIES, LLC (US) | 2017-03-30 | — | — | WO | disclosed |